MTB	Metastatic breast cancer
PD-L1	Programmed death-ligand 1
TNBC	Triple-negative breast cancer
PARP	Poly (ADP-ribose) polymerase
gBRCA	Germline BRCA
CTC	Circulating tumor cell
LoE	Levels of evidence
GR	Grade
AGO	Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group)
MTB	Molecular Tumor Board
ESCAT	ESMO Scale of Clinical Actionability
PFS	Progression-free survival
PFSr	Progression-free survival ratio
HR	Hormone receptor
ER	Estrogen receptor
PR	Progesterone receptor
HER2	Human epidermal growth factor receptor 2
NGS	Next-generation sequencing
MTA	Molecular targeted agents
OR	Overall response rate
SD	Stable disease
PR	Partial remission